Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Campbell, Esther J; Tesson, Mathias; Doogan, Flora; Mohammed, Zahra MA; Mallon, Elizabeth; Edwards, Joanne (2016)
Publisher: Nature Publishing Group
Journal: British Journal of Cancer
Languages: English
Types: Article
Subjects: Molecular Diagnostics, combined endocrine receptor, breast cancer, oestrogen receptor, progesterone receptor, endocrine therapy
Background: The functional role of progesterone receptor (PR) signalling was previously unclear and PR testing in breast cancer is\ud controversial. Recent defining work has highlighted the functional crosstalk that exists between the oestrogen receptor (ER) and PR. The\ud purpose of this retrospective cohort study was to compare the prognostic value of the combined ER and PR score with either ER or PR alone.\ud Methods: Tumour Allred ER and PR scores were reclassified as negative, low and high. The combined endocrine receptor (CER)\ud was calculated as the average of the reclassified ER and PR scores, resulting in three groups: CER negative, impaired and high.\ud Cox proportional hazards models were used to estimate disease-free survival (DFS) and breast cancer-specific survival (BCSS).\ud Results: The CER was a more powerful predictor of 5-year DFS and BCSS than either ER or PR alone. In multivariate analysis that included\ud ER, PR and CER, only CER remained an independent prognostic variable for 5-year DFS (hazard ratio (HR) 0.393; CI: 0.283–0.548,\ud P¼ 0.00001) and BCSS (HR 0.553; CI: 0.423–0.722; P¼ 2.506 10 8\ud ). In ER-positive (ERþ ) patients impaired CER was an independent\ud marker of poor outcome for 5-year DFS (HR 2.469; CI: 1.049–5.810; P¼ 0.038) and BCSS (HR 1.946; CI: 1.054–3.596; P¼ 0.033) in multivariate\ud analysis that included grade, lymph node, tumour size, HER2 status and PR status. The results were validated in a separate cohort of\ud patients.\ud Conclusions: Combined endocrine receptor is a more powerful discriminator of patient outcome than either ER or PR alone. Economical\ud and simple, it can identify risk in ERþ early breast cancer and potentially be used for adjuvant cytotoxic chemotherapy decision-making.

Share - Bookmark

Cite this article

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok